Nuevas alternativas en el tratamiento del cancer gástrico avanzado

Garrido, Marcelo; Melgoza, Geraldine; Galindo, Héctor; Madrid, Jorge; Sánchez, César; Nervi, Bruno; Álvarez, Manuel; Orellana, Eric

Abstract

Background: Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. Aim: To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy). Material and methods: Patients with stage IVgastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed. Results: Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months. Conclusions: FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity

Más información

Título según SCIELO: Nuevas alternativas en el tratamiento del cancer g�strico avanzado
Título de la Revista: REVISTA MEDICA DE CHILE
Volumen: 135
Número: 11
Editorial: SOC MEDICA SANTIAGO
Fecha de publicación: 2007
Página de inicio: 1380
Página final: 1387
Idioma: es
URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001100003&lng=en&nrm=iso&tlng=en
DOI:

10.4067/S0034-98872007001100003

Notas: SCIELO